Fig. 4From: Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapyProgression-free survival (lower triangle) and overall survival (upper triangle) comparison profile for advanced NSCLC under subgroup analysis stratified by PDL-1 expression status. A PD-L1 negative. B PD-L1 intermediate. C PD-L1 highBack to article page